[go: up one dir, main page]

MX2019003311A - Metodos para tratamiento de cancer de ovario. - Google Patents

Metodos para tratamiento de cancer de ovario.

Info

Publication number
MX2019003311A
MX2019003311A MX2019003311A MX2019003311A MX2019003311A MX 2019003311 A MX2019003311 A MX 2019003311A MX 2019003311 A MX2019003311 A MX 2019003311A MX 2019003311 A MX2019003311 A MX 2019003311A MX 2019003311 A MX2019003311 A MX 2019003311A
Authority
MX
Mexico
Prior art keywords
methods
ovarian cancer
treating ovarian
treating
treatment
Prior art date
Application number
MX2019003311A
Other languages
English (en)
Other versions
MX390571B (es
Inventor
Hattersley Gary
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of MX2019003311A publication Critical patent/MX2019003311A/es
Publication of MX390571B publication Critical patent/MX390571B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con métodos para el tratamiento de cáncer de ovario.
MX2019003311A 2016-09-27 2017-09-27 Metodos para tratamiento de cancer de ovario. MX390571B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400495P 2016-09-27 2016-09-27
PCT/US2017/053834 WO2018064231A1 (en) 2016-09-27 2017-09-27 Methods for treating ovarian cancer

Publications (2)

Publication Number Publication Date
MX2019003311A true MX2019003311A (es) 2019-07-08
MX390571B MX390571B (es) 2025-03-20

Family

ID=61760096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003311A MX390571B (es) 2016-09-27 2017-09-27 Metodos para tratamiento de cancer de ovario.

Country Status (23)

Country Link
US (2) US20200009085A1 (es)
EP (1) EP3518911B1 (es)
JP (1) JP2019532934A (es)
KR (2) KR20230152814A (es)
CN (1) CN109715149A (es)
AU (1) AU2017336564A1 (es)
BR (1) BR112019004276A2 (es)
CA (1) CA3036568A1 (es)
CY (1) CY1125266T1 (es)
ES (1) ES2898072T3 (es)
HR (1) HRP20211804T1 (es)
HU (1) HUE057064T2 (es)
IL (1) IL265537B2 (es)
LT (1) LT3518911T (es)
MX (1) MX390571B (es)
NZ (1) NZ751032A (es)
PL (1) PL3518911T3 (es)
PT (1) PT3518911T (es)
RS (1) RS62660B1 (es)
SG (2) SG10202104282SA (es)
SI (1) SI3518911T1 (es)
SM (1) SMT202100667T1 (es)
WO (1) WO2018064231A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
CN1927815A (zh) * 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
MX2009013575A (es) * 2007-06-12 2010-07-02 Schering Corp Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
KR20160021281A (ko) * 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 아제티딘 에스트로겐 수용체 조절제 및 이의 용도
CN104436194B (zh) * 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
SG11201607334YA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN112375077A (zh) * 2014-12-18 2021-02-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN105848374A (zh) * 2015-01-12 2016-08-10 芋头科技（杭州）有限公司 一种灯光控制系统及方法
EP3250134B1 (en) * 2015-01-28 2022-02-16 DePuy Synthes Products, Inc. Battery enclosure for sterilizeable surgical tools having thermal insulation
IL255189B2 (en) * 2015-04-29 2024-04-01 Radius Pharmaceuticals Inc A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer

Also Published As

Publication number Publication date
SI3518911T1 (sl) 2022-02-28
AU2017336564A1 (en) 2019-03-14
MX390571B (es) 2025-03-20
LT3518911T (lt) 2021-12-10
CN109715149A (zh) 2019-05-03
ES2898072T3 (es) 2022-03-03
EP3518911B1 (en) 2021-08-25
EP3518911A4 (en) 2020-05-13
KR20230152814A (ko) 2023-11-03
PT3518911T (pt) 2021-11-11
IL265537A (en) 2019-05-30
SG11201901759XA (en) 2019-04-29
CA3036568A1 (en) 2018-04-05
IL265537B2 (en) 2023-04-01
BR112019004276A2 (pt) 2019-06-04
HUE057064T2 (hu) 2022-04-28
SG10202104282SA (en) 2021-06-29
RS62660B1 (sr) 2021-12-31
NZ751032A (en) 2025-08-29
PL3518911T3 (pl) 2022-02-07
US20200009085A1 (en) 2020-01-09
HRP20211804T1 (hr) 2022-02-18
IL265537B (en) 2022-12-01
WO2018064231A1 (en) 2018-04-05
RU2019108382A3 (es) 2020-12-28
EP3518911A1 (en) 2019-08-07
JP2019532934A (ja) 2019-11-14
US20230129787A1 (en) 2023-04-27
SMT202100667T1 (it) 2022-01-10
RU2019108382A (ru) 2020-10-29
KR20190058568A (ko) 2019-05-29
CY1125266T1 (el) 2023-03-24

Similar Documents

Publication Publication Date Title
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
IL263925A (en) Methods of treating ovarian cancer
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
UY37018A (es) Inhibidores bicíclicos de pad4
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
PH12017501879A1 (en) Methods for treating cancer
UY36286A (es) Tratamientos médicos basados en anamorelina
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
MX2018001315A (es) Inhibidores de fucosidasa.
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
BR112017025264A2 (pt) tratamento de prurido
MX2019002673A (es) Composiciones y metodos para tratar demencia.
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.